These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 14678293)

  • 41. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women.
    Oh ES; Rhee EJ; Oh KW; Lee WY; Baek KH; Yoon KH; Kang MI; Yun EJ; Park CY; Choi MG; Yoo HJ; Park SW
    Metabolism; 2005 Jan; 54(1):49-54. PubMed ID: 15562379
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males.
    Oh KW; Rhee EJ; Lee WY; Kim SW; Baek KH; Kang MI; Yun EJ; Park CY; Ihm SH; Choi MG; Yoo HJ; Park SW
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):92-8. PubMed ID: 15638876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients.
    Zojer N; Brenner K; Beke D; Kudlacek S; Hawa G; Woloszczuk W; Hofbauer LC; Pecherstorfer M
    Anticancer Res; 2005; 25(5):3607-12. PubMed ID: 16101188
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
    Takayanagi H; Iizuka H; Juji T; Nakagawa T; Yamamoto A; Miyazaki T; Koshihara Y; Oda H; Nakamura K; Tanaka S
    Arthritis Rheum; 2000 Feb; 43(2):259-69. PubMed ID: 10693864
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
    Cheung J; Mak YT; Papaioannou S; Evans BA; Fogelman I; Hampson G
    J Endocrinol; 2003 Jun; 177(3):423-33. PubMed ID: 12773123
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
    J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.
    Xu S; Wang Y; Lu J; Xu J
    Rheumatol Int; 2012 Nov; 32(11):3397-403. PubMed ID: 22057136
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.
    Haynes DR; Crotti TN; Loric M; Bain GI; Atkins GJ; Findlay DM
    Rheumatology (Oxford); 2001 Jun; 40(6):623-30. PubMed ID: 11426018
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
    Mezquita-Raya P; de la Higuera M; García DF; Alonso G; Ruiz-Requena ME; de Dios Luna J; Escobar-Jiménez F; Muñoz-Torres M
    Osteoporos Int; 2005 Nov; 16(11):1368-74. PubMed ID: 15711777
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples.
    Seck T; Diel I; Bismar H; Ziegler R; Pfeilschifter J
    Eur J Endocrinol; 2001 Aug; 145(2):199-205. PubMed ID: 11454517
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
    Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
    Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Are activated T cells regulators of bone metabolism in children with Crohn disease?
    Sylvester FA; Davis PM; Wyzga N; Hyams JS; Lerer T
    J Pediatr; 2006 Apr; 148(4):461-6. PubMed ID: 16647405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease.
    Hegedus D; Ferencz V; Lakatos PL; Meszaros S; Lakatos P; Horvath C; Szalay F
    J Bone Miner Res; 2002 Nov; 17(11):1961-7. PubMed ID: 12412803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
    Jung K; Stephan C; Semjonow A; Lein M; Schnorr D; Loening SA
    J Urol; 2003 Dec; 170(6 Pt 1):2302-5. PubMed ID: 14634401
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
    Fazzalari NL; Kuliwaba JS; Atkins GJ; Forwood MR; Findlay DM
    J Bone Miner Res; 2001 Jun; 16(6):1015-27. PubMed ID: 11393778
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand.
    Ziegler S; Niessner A; Richter B; Wirth S; Billensteiner E; Woloszczuk W; Slany J; Geyer G
    Metabolism; 2005 Jul; 54(7):935-8. PubMed ID: 15988704
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).
    Buxton EC; Yao W; Lane NE
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3332-6. PubMed ID: 15240611
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PTH differentially regulates expression of RANKL and OPG.
    Huang JC; Sakata T; Pfleger LL; Bencsik M; Halloran BP; Bikle DD; Nissenson RA
    J Bone Miner Res; 2004 Feb; 19(2):235-44. PubMed ID: 14969393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.